WATERTOWN, Mass., April 09, 2026
C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche, focusing on the development of degrader-antibody conjugates (DACs), an innovative therapeutic modality designed to enhance precision cancer treatment. This strategic agreement strengthens a decade-long partnership and aims to combine targeted protein degradation (TPD) with antibody-drug conjugate (ADC) technologies, enabling the development of next-generation oncology therapies with improved efficacy and selectivity. The collaboration highlights the increasing importance of multi-modality drug development approaches in addressing complex and resistant cancers.
Next-Generation DAC Technology Targets Hard-to-Treat Cancers
The collaboration is centered on advancing DAC technology, which integrates the delivery precision of monoclonal antibodies with the catalytic efficiency of protein degraders, allowing for targeted destruction of disease-causing proteins rather than simple inhibition. This approach represents a significant evolution beyond traditional ADCs, which have historically faced challenges such as limited therapeutic margins. By leveraging degrader payloads that act catalytically, DACs offer the potential for a superior therapeutic index and enhanced anti-tumor activity.
Under the agreement, C4 Therapeutics will utilize its proprietary TORPEDO® platform to design highly selective degrader payloads, while Roche will focus on antibody selection, conjugation, and clinical development. The collaboration will initially target two oncology programs, with an option to expand into a third target, demonstrating the scalability and long-term innovation potential of this approach in oncology drug development.
$1 Billion Deal Signals Strong Biopharma Innovation Value
Advertisement
The financial structure of the agreement reflects the high commercial and scientific value of DAC-based therapies. C4 Therapeutics will receive a $20 million upfront payment, along with eligibility for over $1 billion in milestone payments tied to discovery, development, regulatory approvals, and commercialization achievements. Additionally, the company will receive tiered royalties on future global sales, reinforcing the long-term revenue potential of this partnership.
Roche will lead preclinical and clinical development as well as global commercialization, leveraging its extensive expertise in oncology pipelines, regulatory pathways, and large-scale manufacturing. Meanwhile, C4 Therapeutics will focus on innovative drug design and degrader optimization, strengthening its position as a leader in targeted protein degradation science. This collaboration marks the third partnership between the two companies, underscoring a strong foundation of scientific trust and shared innovation goals.
Implications for cGxP, Biologics, and Future Oncology Therapies
The expansion of this partnership has significant implications for the biopharmaceutical industry and cGxP frameworks, particularly in the areas of complex biologics development, advanced drug conjugation, and regulatory compliance. DACs represent a new frontier in oncology, offering the ability to target previously “undruggable” proteins and overcome resistance mechanisms that limit current therapies.
From a cGxP perspective, the development of DACs involves stringent quality control, advanced manufacturing processes, and regulatory validation across preclinical and clinical stages. The integration of AI-driven drug design, proteomics, and DNA-encoded library technologies within the TORPEDO® platform further demonstrates how data-driven innovation is accelerating drug discovery while maintaining compliance with global regulatory standards.
This collaboration also reflects a broader industry trend toward precision medicine and targeted therapies, where combining multiple scientific approaches can significantly improve patient outcomes and treatment specificity. As DAC programs advance into clinical development, they are expected to play a critical role in shaping the future of oncology treatment strategies.
The expanded agreement between C4 Therapeutics and Roche represents a major milestone in biopharmaceutical innovation, positioning degrader-antibody conjugates (DACs) as a transformative approach in cancer therapy. By combining cutting-edge degradation technology with antibody precision and global development expertise, the partnership aims to deliver highly effective, targeted treatments for patients with difficult-to-treat cancers, reinforcing the importance of collaboration, scientific innovation, and regulatory excellence in modern drug development.
Source: C4 Therapeutics, Roche press release
